A Phase 1b/2 Open-Label, Dose Escalation And Expansion Study Of Orally Administered Vrx-3996 And Valganciclovir In Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies Read more
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study Of Bendamustine And Rituximab (BR) Alone Versus In Combination With Acalabrutinib (ACP 196) In Subjects With Previously Untreated Mantle Cell Lymphoma Read more
A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study To Assess The Safety, Tolerability, Pharmacokinetics And Preliminary Antitumor Activity Of Ascending Doses Of AZD5991 In Subjects With Relapsed Or Refractory Haematologic Malignancies Read more
Astrazeneca/ Treatment Patterns, Outcomes, And Patient-Reported Health-Related Quality Of Life: A Prospective Disease Registry Of Patients With Mantle Cell Lymphoma Treated With Novel Agents Read more
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of BTCT4465A In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin?S Lymphoma And Chronic Lymphocytic Leukemia Read more
Outcomes And Prognostic Factors Of Patients Diagnosed With High-Grade B-Cell Lymphoma, Not Otherwise Specified: A Multi-Institutional Retrospective Study Read more
An Open-Label, Phase 1/2 Study Of JCAR017 In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma (017004) Read more
A Global Randomized Multicenter Phase 3 Trial Of JCAR017 Compared To Standard Of Care In Adult Subjects With High-Risk, Second-Line, Transplant-Eligible Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (TRANSFORM). Read more
